The Effect of Oxymatrine on Serum GLP-1 and DPP-4 Levels in Healthy Male Rats
Öz
Aim: Oximatrine (OMT), a bioactive quinolizidine alkaloid isolated from Sophora flavescens, demonstrates various pharmacological properties, including antiinflammatory, antiviral, and emerging metabolic regulatory effects. Although its glucose-lowering potential has been recognized, its effect on the incretin system, particularly glucagon-like peptide-1 (GLP-1) and its regulatory enzyme, dipeptidyl peptidase-4 (DPP4), remains unclear. The purpose of this study is to ascertain the relationship between serum GLP-1 and DPP-4 biomarkers and to examine the effects of OMT applied at varying doses. Materials and Methods: The experiment included 28 male Wistar rats. The rats were grouped as Control (CONT, saline), OMT15 (15 mg/kg OMT), OMT30 (30 mg/kg OMT), and OMT60 (60 mg/kg OMT). Daily applications were administered intraperitoneally for 28 days. Twenty-four hours after the last application, blood was taken from the animals via cardiac puncture under urethane anesthesia. Results: Chronic OMT administration significantly impacted both GLP-1 and DPP-4 levels. Compared to the CONT group, the OMT15, OMT30, and OMT60 groups had statistically significantly higher levels of GLP-1 and DPP-4. Likewise, the GLP-1 and DPP-4 levels of the OMT60 group were statistically higher than OMT15 and OMT30 groups. A noteworthy positive correlation was identified with individual serum GLP-1 and DPP-4 levels in all animals treated with OMT. Additionally, a noteworthy positive relationship was observed with GLP-1 and DPP-4 levels. Conclusion: Consequently, OMT utilization has been observed to increase GLP-1 and DPP-4 levels, and a positive correlation with these parameters has been observed. The results show the potential effects of OMT on mechanisms related to the incretin system and provide a basis for further studies
Anahtar Kelimeler
Glucagon-like peptide 1, dipeptidyl peptidase 4, incretin hormones, glucose homeostasis.
Kaynakça
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. doi:10.1038/nrendo.2017.151
- Drucker DJ. The expanding landscape of GLP-1 medicines. Nat Med. 2026;32(1):47-57. doi:10.1038/s41591-025-04124-5
- Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463-474. doi:10.1038/s41569-023-00849-3
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
- Beutler LR. GLP-1 physiology and pharmacology along the gut-brain axis. J Clin Invest. 2026;136(2)doi:10.1172/jci194744
- Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
- Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. Front Endocrinol. 2019;10:260. doi:10.3389/fendo.2019.00260
- Deacon CF. Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Correction. Front Endocrinol. 2019: Volume 10 - 2019. doi:10.3389/fendo.2019.00275
- Gaggini M, Sabatino L, Suman AF, et al. Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology. Cells-Basel. 2025;14(5):387.
- Villa Chagas H, Laurindo LF, Dogani Rodrigues V, et al. Can DPP-4 Inhibitors Improve Glycemic Control and Preserve Beta-Cell Function in Type 1 Diabetes Mellitus? A Systematic Review. Diseases. 2026;14(1):28.